Supriya Lifescience [SUPRIYA] vs Biocon [BIOCON] Detailed Stock Comparison
Supriya Lifescience
NSE
Loading...
Biocon
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Supriya Lifescience wins in 13 metrics, Biocon wins in 7 metrics, with 0 ties. Supriya Lifescience appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Supriya Lifescience | Biocon | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 33.17 | 108.04 | Supriya Lifescience |
| Price-to-Book Ratio | 5.89 | 1.92 | Biocon |
| Debt-to-Equity Ratio | 0.54 | 66.26 | Supriya Lifescience |
| PEG Ratio | -1.51 | -1.13 | Supriya Lifescience |
| EV/EBITDA | 23.37 | 19.02 | Biocon |
| Profit Margin (TTM) | 26.16% | 2.44% | Supriya Lifescience |
| Operating Margin (TTM) | 31.19% | 7.46% | Supriya Lifescience |
| EBITDA Margin (TTM) | 31.19% | 7.46% | Supriya Lifescience |
| Return on Equity | 18.86% | 3.66% | Supriya Lifescience |
| Return on Assets (TTM) | 16.90% | 1.72% | Supriya Lifescience |
| Free Cash Flow (TTM) | $22.99M | $17.18B | Biocon |
| Dividend Yield | 0.27% | 0.26% | Supriya Lifescience |
| 1-Year Return | 28.39% | 1.70% | Supriya Lifescience |
| Price-to-Sales Ratio (TTM) | 8.67 | 2.93 | Biocon |
| Enterprise Value | $58.32B | $613.72B | Biocon |
| EV/Revenue Ratio | 8.57 | 3.89 | Biocon |
| Gross Profit Margin (TTM) | 78.10% | 64.06% | Supriya Lifescience |
| Revenue per Share (TTM) | $85 | $131 | Biocon |
| Earnings per Share (Diluted) | $22.11 | $3.21 | Supriya Lifescience |
| Beta (Stock Volatility) | 0.18 | 0.23 | Supriya Lifescience |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Supriya Lifescience vs Biocon Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Supriya Lifescience | -0.31% | 4.15% | 10.38% | 0.70% | -8.05% | -3.36% |
| Biocon | 1.67% | 3.94% | -2.57% | -5.93% | 1.88% | -4.49% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Supriya Lifescience | 28.39% | 143.25% | 51.15% | 51.15% | 51.15% | 51.15% |
| Biocon | 1.70% | 24.54% | -22.05% | 376.72% | 414.31% | 787.95% |
News Based Sentiment: Supriya Lifescience vs Biocon
Supriya Lifescience
News based Sentiment: MIXED
October saw Supriya Lifescience secure a key regulatory certification, alongside positive insider activity, but these were countered by a significant decline in quarterly revenue and profit. This creates a mixed investment picture, balancing long-term potential with short-term concerns.
Biocon
News based Sentiment: POSITIVE
The month's narrative centers around Biocon's positive developments – entry into the US market with biosimilars and consideration of early NCD redemption – which suggest a strengthening investment case. While trading volume was lower than average, the overall tone is optimistic.
Performance & Financial Health Analysis: Supriya Lifescience vs Biocon
| Metric | SUPRIYA | BIOCON |
|---|---|---|
| Market Information | ||
| Market Cap | ₹62.35B | ₹470.24B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 452,364 | 3,963,018 |
| 90 Day Avg. Volume | 229,303 | 2,555,718 |
| Last Close | ₹731.10 | ₹352.25 |
| 52 Week Range | ₹511.40 - ₹842.00 | ₹291.00 - ₹406.00 |
| % from 52W High | -13.17% | -13.24% |
| All-Time High | ₹842.00 (Mar 31, 2025) | ₹487.75 (Dec 21, 2020) |
| % from All-Time High | -13.17% | -27.78% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.10% | 0.15% |
| Quarterly Earnings Growth | -0.22% | -0.95% |
| Financial Health | ||
| Profit Margin (TTM) | 0.26% | 0.02% |
| Operating Margin (TTM) | 0.31% | 0.07% |
| Return on Equity (TTM) | 0.19% | 0.04% |
| Debt to Equity (MRQ) | 0.54 | 66.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹124.44 | ₹180.66 |
| Cash per Share (MRQ) | ₹9.83 | ₹38.10 |
| Operating Cash Flow (TTM) | ₹1.87B | ₹17.78B |
| Levered Free Cash Flow (TTM) | ₹1.88B | ₹10.13B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.27% | 0.26% |
| Last 12-Month Dividend | ₹1.80 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Supriya Lifescience vs Biocon
| Metric | SUPRIYA | BIOCON |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 33.17 | 108.04 |
| Forward P/E | 24.28 | 34.96 |
| PEG Ratio | -1.51 | -1.13 |
| Price to Sales (TTM) | 8.67 | 2.93 |
| Price to Book (MRQ) | 5.89 | 1.92 |
| Market Capitalization | ||
| Market Capitalization | ₹62.35B | ₹470.24B |
| Enterprise Value | ₹58.32B | ₹613.72B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.57 | 3.89 |
| Enterprise to EBITDA | 23.37 | 19.02 |
| Risk & Other Metrics | ||
| Beta | 0.18 | 0.23 |
| Book Value per Share (MRQ) | ₹124.44 | ₹180.66 |
Financial Statements Comparison: Supriya Lifescience vs Biocon
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SUPRIYA | BIOCON |
|---|---|---|
| Revenue/Sales | ₹1.45B | ₹39.10B |
| Cost of Goods Sold | ₹317.72M | ₹14.05B |
| Gross Profit | ₹1.13B | ₹25.05B |
| Research & Development | N/A | ₹-346.00M |
| Operating Income (EBIT) | ₹452.50M | ₹2.94B |
| EBITDA | ₹543.75M | ₹8.29B |
| Pre-Tax Income | ₹474.12M | ₹969.00M |
| Income Tax | ₹126.22M | ₹77.00M |
| Net Income (Profit) | ₹347.90M | ₹892.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SUPRIYA | BIOCON |
|---|---|---|
| Cash & Equivalents | ₹759.97M | ₹32.27B |
| Total Current Assets | ₹4.37B | ₹162.86B |
| Total Current Liabilities | ₹821.62M | ₹143.34B |
| Long-Term Debt | ₹50.57M | ₹129.45B |
| Total Shareholders Equity | ₹9.97B | ₹277.13B |
| Retained Earnings | ₹7.82B | ₹189.59B |
| Property, Plant & Equipment | ₹645.91M | ₹4.32B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SUPRIYA | BIOCON |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SUPRIYA | BIOCON |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 452,364 | 3,963,018 |
| Average Daily Volume (90 Day) | 229,303 | 2,555,718 |
| Shares Outstanding | 80.48M | 1.20B |
| Float Shares | 25.53M | 524.74M |
| % Held by Insiders | 0.72% | 0.55% |
| % Held by Institutions | 0.03% | 0.24% |
Dividend Analysis & Yield Comparison: Supriya Lifescience vs Biocon
| Metric | SUPRIYA | BIOCON |
|---|---|---|
| Last 12-Month Dividend | ₹1.80 | ₹1.00 |
| Last 12-Month Dividend Yield | 0.27% | 0.26% |
| 3-Year Avg Annual Dividend | ₹0.80 | ₹1.33 |
| 3-Year Avg Dividend Yield | 0.17% | 0.36% |
| 3-Year Total Dividends | ₹2.40 | ₹4.00 |
| Ex-Dividend Date | Sep 04, 2025 | Jul 04, 2025 |